Sign In
Buy CPRX
$31.49
+0 (+0%)
At Close: Jul 31, 2026
Catalyst (CPRX) Upgraded to Buy: What Does It Mean for the Stock?
01:00pm, Tuesday, 01'st Oct 2024
Catalyst (CPRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
08:03am, Tuesday, 01'st Oct 2024
CORAL GABLES, Fla., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan
06:00am, Tuesday, 24'th Sep 2024
CORAL GABLES, Fla., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, d
Santhera Announces Half-Year 2024 Financial Results and Provides Corporate Update
01:00am, Thursday, 12'th Sep 2024
Ad hoc announcement pursuant to Art. 53 LR A conference call will be held on September 12, 2024, at 14:30 CEST / 13:30 BST / 08:30 EDT.
Why Is Catalyst (CPRX) Up 8.3% Since Last Earnings Report?
12:38pm, Friday, 06'th Sep 2024
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
08:03am, Tuesday, 20'th Aug 2024
CORAL GABLES, Fla., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, dev
Wall Street Analysts See a 56.65% Upside in Catalyst (CPRX): Can the Stock Really Move This High?
10:56am, Thursday, 15'th Aug 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 56.7% in Catalyst (CPRX). While the effectiveness of this highly sought-after metric is questionable, the posit
Recent Price Trend in Catalyst (CPRX) is Your Friend, Here's Why
09:51am, Thursday, 15'th Aug 2024
If you are looking for stocks that are well positioned to maintain their recent uptrend, Catalyst (CPRX) could be a great choice. It is one of the several stocks that passed through our "Recent Price
Top 3 Health Care Stocks That May Crash In August
08:35am, Wednesday, 14'th Aug 2024
As of Aug 14, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions.
Catalyst Pharmaceuticals, Inc. (CPRX) Q2 2024 Earnings Call Transcript
01:30pm, Thursday, 08'th Aug 2024
Call End: Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX ) Q2 2024 Earnings Conference Call August 08, 2024, 08:30 AM ET Company Participants Michael Kalb - Chief Financial Officer Richard Daly - Preside
Catalyst (CPRX) Rises as Q2 Earnings & Revenues Beat Estimates
10:45am, Thursday, 08'th Aug 2024
Catalyst (CPRX) gains as it reports strong second-quarter results, wherein earnings and revenues beat the Zacks Consensus Estimate, primarily driven by strong Firdapse sales.
Catalyst (CPRX) Reports Q2 Earnings: What Key Metrics Have to Say
09:30pm, Wednesday, 07'th Aug 2024
While the top- and bottom-line numbers for Catalyst (CPRX) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare t
Catalyst Pharmaceutical (CPRX) Beats Q2 Earnings and Revenue Estimates
08:40pm, Wednesday, 07'th Aug 2024
Catalyst Pharmaceutical (CPRX) came out with quarterly earnings of $0.56 per share, beating the Zacks Consensus Estimate of $0.42 per share. This compares to earnings of $0.33 per share a year ago.
Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
04:11pm, Wednesday, 07'th Aug 2024
Delivered Robust Revenue Performance, Fueled by Exceptional Commercial Execution and Early Success of the U.S. AGAMREE® Product Launch
CORAL GABLES, Fla., July 24, 2024 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, de
